HealthFirst Talks: COVID-19 Trends: Facts, Misinformation and Late-Breaking News

With vaccines rolling out around the globe, the “end” of the COVID-19 pandemic may be in sight – but there are still plenty of hot topics to tackle in exploring how the world has responded and shifted in the wake of this uncertain era.

On this episode of HealthFirst Talks, Dr. Scott A. Cohen of the Bassett Healthcare Network and infection prevention specialist Dr. Fiona Collins acted as expert panelists, sharing their front-line insights about the faces, misinformation and late-breaking news surrounding what many hope will prove the pandemic’s closing chapter.

One of the central issues surrounds the vaccines, themselves. Many people are unsure about the vaccines’ safety or efficacy, particularly since those available were accelerated through the approval pipeline so quickly. There are also lingering questions about which vaccine is “better” and how they differ.

Cohen and Collins dove into this topic, explaining how money and a streamlined approval process empowered a vaccine to get into the arms of people more quickly than ever before.

The duo also touched on a range of other topics, such as how the vaccines were actually researched and produced, the practicalities of the rollout and overcoming supply chain challenges, and where the world might go from here both in terms of future vaccines and healthcare, overall.

Follow us on social media for the latest updates in B2B!

Twitter – @MarketScale
Facebook – facebook.com/marketscale
LinkedIn – linkedin.com/company/marketscale

Recent Episodes

In the rapidly advancing field of cancer immunotherapy, accurately modeling the tumor microenvironment (TME) has become essential to improving the predictive power of preclinical drug testing. As immune-modulating therapies surge forward, with over 4,000 immune modulators in development globally, scientists are refining assay technologies that maintain the complexity of patient-specific tumor biology. In vitro platforms…

As cancer immunotherapy continues to reshape treatment landscapes, fine-tuning T-cell responses has become a critical frontier. Recent advances in 3D organoid models and high-content imaging are enabling scientists to closely mimic patient-specific tumor environments—unlocking insights into how T cells behave, respond, and falter under immune checkpoint blockade. With over 4,000 immune modulators in clinical…

As immunotherapy revolutionizes cancer treatment, the need for physiologically relevant preclinical models becomes more urgent than ever. Despite the success of immune checkpoint inhibitors, a large majority of patients fail to achieve long-lasting responses, prompting researchers to explore more complex and predictive assays. The cancer immunity cycle, first described in 2013, remains a central framework…